BigBear.ai to Report Second Quarter 2024 Results on August 1, 2024
BigBear.ai to Report Second Quarter 2024 Results on August 1, 2024
BigBear.ai (NYSE: BBAI), a leading technology provider of AI for enterprise and defense, today announced that it will publish its second quarter earnings release on Thursday, August 1, 2024, at approximately 4:15 pm ET. The earnings release can be accessed on the Company’s investor relations website: https://ir.bigbear.ai. While BigBear.ai will not host an earnings call for this announcement, a shareholder letter from the CEO will again be provided.
About BigBear.ai
BigBear.ai is a leading provider of AI-powered decision intelligence solutions for national security, digital identity, and supply chain management. Customers and partners rely on BigBear.ai’s artificial intelligence and predictive analytics capabilities in highly complex, distributed, mission-based operating environments. Headquartered in Columbia, Maryland, BigBear.ai is a public company traded on the NYSE under the symbol BBAI. For more information, visit https://bigbear.ai and follow BigBear.ai on LinkedIn: @BigBear.ai and X: @BigBearai.
Ryan Stenger
media@bigbear.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718827540/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks